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Abstract Heart failure (HF) patients are at high risk of hos-
pital readmission, which contributes to substantial health care
costs. There is great interest in strategies to reduce rehospital-
ization for HF. However, many readmissions occur within
30 days of initial hospital discharge, presenting a challenge
for interventions to be instituted in a short time frame.
Potential strategies to reduce readmissions for HF can be clas-
sified into three different forms. First, patients who are at high
risk of readmission can be identified even before their initial
index hospital discharge. Second, ambulatory remote moni-
toring strategies may be instituted to identify early warning
signs before acute decompensation of HF occurs. Finally,
strategies may be employed in the emergency department to
identify low-risk patients who may not need hospital readmis-
sion. If symptoms improve with initial therapy, low-risk
patients could be referred to specialized, rapid outpatient
follow-up care where investigations and therapy can occur
in an outpatient setting.
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Introduction
Heart failure is a major health problem in the developed world
representing a substantial portion of emergency department
(ED) presentations and admissions, and it is a leading reason
for hospitalizations globally [1]. Clinical deteriorations lead-
ing to ED visits and hospital admissions contribute substan-
tially to the more than $108 billion in health care expenditures
for heart failure worldwide [2].
Patients who survive their index admission are also at sig-
nificant risk for readmission. With 30-day readmission esti-
mates of nearly 25 % [3] and 6-month readmission rates as
high as 46 % [4], heart failure is the leading reason for hospi-
talizations among the elderly. There has been great interest in
the concept of preventing readmissions among patients with
heart failure (HF), which has been accelerated further because
hospital-level performance measures on 30-day readmissions
have been linked to financial penalties in the USA [5].
There are three major types of interventions and strategies
that may be employed to lead to a reduction inHF readmissions,
and different settings in which they may be deployed. First, the
earliest time point when a strategy for reducing readmissions
can be initiated is prior to discharge home from hospital.
Second, once patients are in the community, they can be mon-
itored closely such that potential decompensations might be
identified earlier allowing the opportunity to intervene and
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provide timely care. Third, the final opportunity to intervene to
reduce readmissions is in the ED itself where there may be
opportunities to divert patients away from inpatient-based care.
In this review, we will discuss how interventions at each of
these phases could potentially be utilized to reduce 30-day
readmissions among patients with heart failure. Recent at-
tempts to curb high readmission rates through efforts such as
disease management programs, education initiatives, and
biomarker-guided therapy will also be discussed.
Identifying Patients at Risk for Readmission
The first opportunity to prevent readmission occurs before the
patient is discharged from hospital, by the identification of
patients who are at highest risk of readmission. The prediction
of readmission risk begins before the initial discharge because
readmissions can occur even within the first day of discharge.
Dharmarajan et al. reported that over 60 % of all 30-day HF
readmissions occurred within 15 days of initial hospital dis-
charge [6]. Therefore, substantial effort has been devoted to
predict which patients are at risk for readmission, because
identifying those at highest risk of readmission would allow
the maximum allocation of resources to be directed toward
keeping them well at home and out of hospital.
While there have been many published studies aiming to
predict the risk of 30-day readmissions among patients with
HF, there are also substantial variations in the characteristics
that have been associated with a heightened readmission risk.
A recent systematic review by Ross and colleagues thorough-
ly examined literature sources until 2007, examining 112 stud-
ies of various designs and statistical methodologies that exam-
ined patient-level characteristics associated with readmission
[7]. While age and sex were the most commonly included
variables in readmission models (>70% of studies examined),
there was no consistent association among the diverse array of
covariates. Comorbidity measures frequently included condi-
tions such as diabetes mellitus and hypertension but were also
not consistently associated with readmission. The biomarker
B-type natriuretic peptide, the product of a neurohormonal
cascade related to ventricular stretch, was one of the laborato-
ry tests whose elevation was consistently associated with re-
admission (17 of 24 studies containing the variable reported a
significant association). Elevated troponin levels were also
consistently associated with increased readmission risk.
In order to build upon the results of Ross et al., we con-
ducted an updated literature search reexamining the potential
predictors associated with readmission risk. RCTcohorts, pro-
spective cohorts, and retrospective analyses of either hospital-
level or administrative data (i.e., Medicare) were used as evi-
dence sources. We examined a number of outcomes including
all-cause and HF-related readmissions, and composite out-
comes with death.
Demographics
Among the demographic features, age has been inconsistently
associated with HF readmission [8–11], while there was no
significant association between sex and readmission risk in
any of the data sources examined [8, 10, 12–18]. The patient’s
race was associated with readmission risk, with non-
Caucasian patients being most frequently readmitted [10, 13,
15, 19].While comparison of patients based on their insurance
status does introduce some degree of confounding, it is nota-
ble that those with Medicare/Medicaid coverage exhibited
higher risk of readmission [11–13, 18, 20]. Patients of lower
socioeconomic status were often found to be at higher risk of
readmission [13, 14, 20, 21].
Comorbidities
While comorbidities, such as hypertension, renal failure,
chronic obstructive pulmonary disease, peripheral vascular
disease, electrolyte abnormalities, cerebrovascular disease,
cancer, and diabetes mellitus, have been commonly studied,
they are inconsistently associated with readmission when ex-
amined independently [8, 9, 12, 15, 17, 22]. However, comor-
bidities clearly are linked with readmission risk because com-
posite indices such as the Charlson score were associated with
increased HF readmission risk [8, 9]. Furthermore, while psy-
chiatric conditions are increasingly prevalent, comorbidities
such as depression have not been found to be consistently
associated with readmission [9, 12–14, 18, 23–30].
Shorter length of stay during the index hospitalization and
more prior hospitalizations were associated with increased
risk of readmission [8, 10, 11, 15]. The former association
suggests that HF patients with shorter length of stay may be
at greater risk of readmission because they have been inade-
quately decongested. The latter finding suggests that hospital-
ization itself may predispose patients to a state of frailty, which
begets further hospitalization.
Novel Factors
Biomarkers have been found to be associated with higher re-
admission risk, including B-type natriuretic peptide [31–37]
and elevated troponin levels [35, 37–40]. Cystatin C, a rela-
tively new biomarker associated with renal function, is also
significantly associated with readmission risk [35, 41–43].
Modeling Readmission Risk
Predictive models using administrative or clinical data sources
have great potential utility. Ross and colleagues identified five
studies [44–48] whose primary purpose was generation of a
predictive model [7]. The majority of studies utilized
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retrospective data from either administrative databases or ran-
domized controlled trial cohorts. There was substantial vari-
ability in the number of patients involved (ranging from 257 to
42,731), follow-up duration (60 days to 1 year), and variation
in outcomes from hospital readmission, composite of readmis-
sion or death, or heart-failure-specific readmission. The c-
statistics provided in three of the five studies was modest,
ranging from 0.60 and 0.69.
Our review identified an additional five studies modeling
heart failure readmission risk. Keenan and colleagues [49]
developed an administrative claims model approved by the
National Quality Forum to estimate hospital-specific readmis-
sion rates for Medicare patients hospitalized with heart failure.
Both heart failure hospitalization and candidate model vari-
ables were based on the presence of ICD-9 diagnostic codes
within the 12 months prior to index hospitalization. Of 189
candidate variables assessed for inclusion, 37 (2 demographic,
9 cardiovascular, 26 comorbidity) were included in the final
model, which was developed using multiple logistic regres-
sion analysis. With 567,447 heart failure hospitalizations ex-
amined, the c-statistic of their proposed model was 0.61.
Amarasingham and colleagues [13] developed a novel
model using routinely available admission variables that are
present in electronic medical records within the first 24 h of
hospital presentation. This retrospectively examined cohort of
1372 patients at a single center, Parkland Memorial Hospital
in Dallas, Texas, was identified using a principal admission
diagnosis code of heart failure. The crude 30-day readmission
rate was 24.7 %, and the model c-statistic was 0.72. Two
important features distinguish this model from others. First,
their model depends on easily attainable administrative data
available generally at the time of admission. Second, the
group identified important markers of social behavior that
could indicate a fragile social situation prone to readmission
risk. These markers included the number of address changes
in the past year, number of ED visits in the past year, and a
history of confirmed cocaine use.
To supplement the claims-based model, Hammill et al.
sought to incorporate clinical variables with the aim of im-
proving discriminatory ability [50]. They obtained clinical
data of patients aged ≥65 years from the Get With The
Guidelines–Heart Failure (GWTG-HF) registry linked to
Medicare claims databases. Excluding stays ≤1 day and elec-
tive hospitalizations, the observed 30-day readmission rate
was 21.9 % and the mortality rate was 10.5 %. While the
“claims-clinical” model included additional variables, such
as left ventricular ejection fraction, heart rate, hemoglobin,
creatinine, serum sodium, systolic blood pressure, and weight,
the c-statistic for predicting readmissions was not significantly
improved compared to the claims-only model.
The length of stay, acuity, Charlson comorbidity, and emer-
gency utilization (LACE) score was developed to assess read-
mission risk for acute coronary syndromes and cancer
diagnoses with a highly discriminative c-statistic of 0.77
[51]. Au et al. sought to validate the model in patients with
heart failure using administrative databases in Alberta,
Canada [8]. They evaluated the model in nearly 60,000
discharged patients and compared it with several other models
including the model proposed by Keenan et al. The primary
outcome of death and readmission at 30 days was determined
to be 18.7 % in this cohort, with 5.1 % mortality and 15.9 %
all-cause readmission rate. The c-statistics of the models and
variants ranged from 0.55 to 0.61.
A summary demonstrating the wide variability of covari-
ates in different clinical models for readmission risk assess-
ment is shown in Table 1.
Ambulatory Strategies
Several ambulatory strategies exist with the goal of keeping
patients out of hospital, thereby preventing readmissions. One
such strategy is a disease management program. Originally
described by Rich et al. [52], a wealth of randomized trials
provide support for this strategy, leading to a reduction in
readmissions longitudinally over time. A Cochrane review
by Takeda and colleagues identified 25 randomized controlled
trials with nearly 6000 total participants classified into case
management interventions, clinical interventions, and multi-
disciplinary interventions [53]. The authors found that case
management interventions significantly reduced heart-
failure-related readmissions at both 6 (odds ratio 0.64) and
12 months (odds ratio 0.47), but there was less significant
impact on all-cause readmissions at 12-month (odds ratio
0.75) follow-up [53]. Interestingly, in a propensity-matched
analysis, Wijeysundera et al. found that care provided in mul-
tidisciplinary heart failure clinics was associated with reduced
mortality but higher readmission rates [54], suggesting that
the two outcomes need to be considered separately when de-
signing a strategy to reduce readmissions. While effective lon-
gitudinally, the multidisciplinary heart failure clinic strategy
has not specifically been applied to the transitional care setting
to reduce 30-day readmissions.
Patients with heart failure may also be readmitted to hos-
pital with decompensations that may have premonitory warn-
ing signs. Earlier detection of physiological abnormalities can
be achieved using technologies such as remote telemonitoring
devices. Telemonitoring interventions can allow measurement
of vital signs, weight, and symptoms “at a distance,” and more
advanced devices offer oximetry, GPS, and accelerometry da-
ta which can be transferred to a central server for monitoring.
Prior studies have shown that higher heart rates in the peri-
discharge transitional period have significant prognostic
implications for HF patients with an increased risk of
HF and cardiovascular hospitalizations with heart rates
>90 beats/min [55]. In addition, higher and lower blood
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Table 1 Clinical prediction
model covariates for HF
readmission










Prior HF x x
Prior MI x
Health services use history
Prior admission/ED visit x x x
Prior missed clinic visit x
Pharmacy use x
Acute presentation features
Daytime ED presentation x
Acute admission x
Length of stay x
Vital signs





Serum sodium x x














Peripheral vascular disease x
Cerebrovascular disease x
Liver disease x




Altered mental status x
Cocaine abuse x
Dementia x
SES socioeconomic status; NYHA New York Heart Association; HF heart failure;MImyocardial infarction; ED
emergency department; BP blood pressure; WBC white blood count; CK creatine kinase; COPD chronic
obstructive pulmonary disease
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pressure peri-discharge has been demonstrated to be asso-
ciated with increased mortality risk [56].
While technologies are available for remote monitoring in
the transitional care period, its role in the pathway of HF pa-
tients after hospital discharge is unclear. This is, in part, due to
the variable results in the published literature, which demon-
strates heterogeneity. Programs vary in the intensity of the in-
tervention, how telemonitored data are treated, and the degree
of patient involvement in obtaining measurements at home.
While an in-depth evaluation of telemonitoring interventions
is outside of the scope of this review, some patterns are evident.
First, remote monitoring of symptoms or physiological
measurements that were less intensive and had little clinical
involvement by nurse and/or physician was generally not ef-
fective. The intensity of the intervention in these negative
studies were demonstrated by non-daily ascertainment of
physiologic measurements or symptoms [57, 58], lack of
nurse involvement in the intervention [59], lack of nurse re-
view on weekends [60, 61], or absence of highly engaged HF
specialist physician response team [62–64], compared to stud-
ies with positive results favoring telemonitoring [65–69]. One
of the trials that did not demonstrate a significant benefit was a
large trial of telemonitoring, which enrolled 1653 patients
[61]. In this study, daily phone calls were made to an automat-
ed voice system, and data were reviewed on weekdays by site
coordinators. There was no significant difference between
telemonitoring and usual care groups in the composite of
death and readmission at 180 days. Although it is the largest
trial to date, many cite low adherence (14 % of patients never
activated their telemonitoring and only 55 % of patients were
adherent throughout the trial period) as an additional caveat in
interpretation.
In contrast, several studies illustrate highly successful ex-
amples in the spectrum of telemonitoring interventions.
Giordano and colleagues [70] offered a unique intervention
in which constant transmission of vital data was supplied
through a mobile phone to a monitoring station for 460 pa-
tients in Italy. Nurses received the data and interacted closely
with treating physicians such that only the physician could
recommend an emergency room visit. A reduction in 1-year
readmission was demonstrated (relative risk 0.56; 95 % con-
fidence interval 0.39, 0.84) with a subsequent mortality bene-
fit and reduction in mean cost of readmission [70].
In Spain, Atienza et al. conducted a randomized trial of
telemonitoring in 338 patients, where the intervention began
prior to hospital discharge [71]. In the pre-discharge phase, a
cardiac nurse emphasized disease knowledge and self-care to
hospitalized patients. In addition to daily remote vital signs
transmission, patients were seen by their primary care provid-
er within 2 weeks and received regular follow-up in the heart
function clinic. Their interventionwas highly successful, dem-
onstrating a significant reduction in events per observation
year and readmissions per patient year. Furthermore, a nearly
twofold reduction in hospital days and a significant mortality
reduction were shown. The importance of specialist involve-
ment was demonstrated in a telemonitoring study conducted in
the USA by Laramee et al.[58] While the primary intervention
(in-hospital discharge planning, diet and fluid recommenda-
tions, and self-monitoring followed by a telephone intervention
in which participants were called every 1 to 3 days with respect
to their symptoms) did not significantly reduce readmission at
90 days, there was a significant impact in the subset of patients
whose cardiologists were more reachable by the surveying
nurse (HF readmission rate 2 vs. 14 %), presumably due to
improved physician response to symptomatic changes [58].
Emergency-Department-Based Strategies to Reduce
Readmissions
The final point where intervention is possible to reduce
readmissions is in the emergency department. We have previ-
ously shown that some patients who present to the ED have a
low risk of mortality [72]. While some of these patients may
have symptoms or other considerations that might require
hospital admission, some low-risk patients can be discharged
home to receive outpatient care. If these low-risk patients im-
prove symptomatically after diuresis while being observed in
the ED, they can be discharged home and a potential readmis-
sion may be averted. To implement this strategy, several com-
ponents of care must be available.
First, a validated risk stratification algorithm must be avail-
able. We have developed the Emergency Heart Failure
Mortality Risk Grade (EHMRG), a clinical risk algorithm that
stratifies risk of 7-day mortality which was derived and vali-
dated in >12,000 patients presenting to the ED (https://ehmrg.
ices.on.ca) [73]. The predictive ability of the EHMRG has
been extended to predict 30-day mortality by the addition of
one more variable, the presence or absence of ST segment
depression on the 12-lead electrocardiogram [74]. The addi-
tion of ST segment depression resulted in a net reclassification
improvement of 17 % compared to the EHMRG 7-day model
alone, for prediction of 30-day mortality risk [74]. The com-
posite of these two risk scores provides a simultaneous esti-
mate of risk at two different points in time (Fig. 1), which we
have termed the EHMRG30-ST model. The ability to deter-
mine that patients are not high risk ofmortality at an early time
and at 30 days is important if outpatient ambulatory care will
be provided during the transition from hospital to home,
which extends up to 30 days post-ED discharge.
Second, the ability to observe the patient before making the
final decision to admit or discharge the patient is beneficial.
This may occur in an observation unit setting, and it is impor-
tant because it allows physicians to determine if there has been
a response to diuretics. Patients who are low risk and have
responded to diuretics are good candidates for discharge
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home. In contrast, patients who are low risk but remain
congested after initial diuretic administration may still require
an admission for further diuresis. These patients could poten-
tially be admitted for a short-stay admission and be rapidly
discharged with outpatient follow-up. During this period of
observation, troponin measurement could be repeated and
the patient could be further monitored. Given the importance
of troponin in prognosis [38], if there is an increase in troponin
into an abnormal range, this might lead the medical team to
admit the patient for investigation if the ischemic disease sta-
tus of the patient is unknown. Other considerations that may
become apparent during the period of observation, including
significant deviations of vital signs, may also lead to the de-
cision to admit rather than discharge home [75].
Third, the ability to follow patients rapidly after discharge
is critically important to this strategy. We have shown that
cardiac specialist care leads to substantial improvement in
survival and readmission-free survival in patients who are
discharged from the ED [76]. The Rapid Ambulatory
Program for Investigation and Diagnosis of HF (RAPID-HF)
provides specialized follow-up care to patients who are
discharged from the ED or observation unit, or after a short-
stay hospital admission (<48 h) in a transitional care clinic
(Fig. 2). Ideally, patients should be followed in the RAPID-
HF clinic within 48 h from index discharge to ensure that they
have responded well to diuretic therapy and to determine if
any adjustment is required. In addition, echocardiography to
determine the underlying left ventricular systolic function, and
laboratory testing to reevaluate electrolytes and renal function
should also be performed. If the presence of ischemic heart
disease is unknown, testing may be performed using myocar-
dial perfusion imaging or coronary angiography, for etiologic
evaluation. The RAPID-HF clinic is a transitional care clinic
that provides care for a maximum of 30 days, after which time,
longitudinal care is transferred to a cardiac specialist or a mul-
tidisciplinary HF clinic. Therefore, the care provided in the
RAPID-HF clinic moves the diagnostic and therapeutic inter-
ventions, which in the past might have been performed in
hospital, into the ambulatory care setting.
Conclusion
Readmissions among heart failure patients after a recent hos-
pital discharge are influenced by multiple potential factors.
While readmissions can occur at any time, there is particular
interest in events occurring within 30 days—a short time
period in which to implement interventions to reduce
Fig. 2 HF risk stratification and
decision-making after emergency
department presentation,
admission, and hospital discharge
Fig. 1 Simultaneous estimation of 7-day and 30-daymortality risks using
the EHMRG algorithms
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readmissions. Interventions that have been shown to have
greater impacts on reducing readmissions tend to be more
intensive in terms of the frequency and type of monitoring,
the engagement of nurses, and involvement of more special-
ized cardiac care in treatment decisions. There does not seem
to be a single component that drives benefit, because as the
degree of the intervention becomes less intense, the benefits
are attenuated. It is for this reason that we need better ways to
identify those heart failure patients who are at the highest risk
of readmission. Specifically, the resources necessary to reduce
readmissions are likely too costly to apply to all patients but
are likely to be most efficiently applied if patients who are at
highest risk and most likely to benefit can receive the highest-
intensity interventions.
Identifying those at high risk of hospital readmission,
however, has been a challenge because of the very modest
predictive capability of most algorithms to identify
high-risk subsets. In addition, the competing risk of
readmissions with death poses another major challenge to
risk stratification modeling. Specifically, characteristics
that lead to high rates of death may be associated with lower
readmission risk if competing risks are not accounted for in
the analysis [3]. Indeed, reducing readmissions as a conse-
quence of higher mortality is clearly an undesired result.
Consequently, there are analytical challenges because read-
mission and death might not be readily combined, as these
two types of events are not equal in severity to justify com-
bining them into a single composite endpoint. While chal-
lenging, it remains important to continue our efforts to
develop risk stratification models for readmission in order
to target interventions and quality improvement strategies
in the most efficient way.
Finally, HF patients who seek care in the emergency
department have varying disease severity, and not all pa-
tients who present within 30 days after initial hospital
discharge need to be readmitted. The ability to identify
those who are low risk of mortality is important so that
these patients can be managed without hospitalization in
an ambulatory care setting that can ensure rapid and spe-
cialized follow-up care. Patients need to be at low risk of
death to ensure that adverse events will not occur while
the transitional care clinic provides the necessary diagnos-
tic tests and therapies that can improve symptoms and
prognosis and ultimately reduce the downstream risk of
hospital readmission.
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